A pioneering project proposes light-controlled drugs to reduce heart damage after a heart attack

The PhotoHeart project is one of those selected in the CaixaResearch call, and will be funded with one million euros to develop a photopharmacological therapy that helps reduce heart damage after suffering a myocardial infarction. The project is led by Dr. Amadeu Llebaria, from the Medicinal Chemistry and Synthesis group (MCS), accredited with the TECNIO seal, and will be developed in a consortium with La Vall d’Hebron Institut de Recerca and The Hopkins University (United States).

PhotoHeart has been one of the 30 projects selected in the CaixaResearch call for Health Research 2021, of the “la Caixa” Foundation. These are biomedical and health research projects of excellence of research centers and universities in Spain and Portugal, which have been endowed with a total of 22.1 million euros to be developed over the next three years.

Full information of this call on this LINK.

 

IQAC-CSIC Communication

From left to right: Medeea Maria Gavrilescu, Lourdes Muñoz, Gerard Torné, Carme Serra, Amadeu Llebaria, Xavier Rovira, Xavier Gomez, Aleix Gonzalez, Juan Lorenzo Catena

You may also be interested

Stanford LEAD leaders and executives visit IQAC and IDAEA to explore cutting-edge health and environmental technologies

HARMONY project launches a pioneering integrated approach for the sustainable management of emerging agricultural pests

IQAC organises the XXVI International Round Table on Nucleosides, Nucleotides and Nucleic Acids

The 2026 edition of Young Researchers’ Day marks a record for participation